Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2989-2999

  Buckel, Lisa ^a,b   Advani, Sunil J ^c   Frentzen, Alexa ^b,c   Zhang, Qian ^b,c   Yu, Yong A ^b,c   Chen, Nanhai G ^b,c   Ehrig, Klaas ^a,b   Stritzker, Jochen ^a,b   Mundt, Arno J ^c   Szalay, Aladar A ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

combination therapy; glioma; radiosensitization; vaccinia virus; VEGF

Indexed keywords

GLAF 1 ANTIBODY; ONCOLYTIC VACCINIA VIRUS GLV 1H164; ONCOLYTIC VACCINIA VIRUS GLV 1H68; ONCOLYTIC VIRUS; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM; GLIOMA; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR ASSOCIATED ENDOTHELIUM; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VACCINIA VIRUS; VIRUS REPLICATION;

COMBINATION THERAPY; GLIOMA; RADIOSENSITIZATION; VACCINIA VIRUS; VEGF;

ANIMALS; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; GLIOMA; HUMANS; MALE; MICE; ONCOLYTIC VIROTHERAPY; RADIATION TOLERANCE; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885671668     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28296     Document Type: Article

References (42)

1. Stupp R, Tonn JC, Brada M, et al. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v190-3.
2. Liu TC, Kirn D,. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429-32.
3. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7: 867-74.
4. Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199-207.
5. Shah AC, Benos D, Gillespie GY, et al. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol 2003; 65: 203-26.
6. Zemp FJ, Corredor JC, Lun X, et al. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 2010; 21: 103-17.
7. Liu TC, Galanis E, Kirn D,. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-17.
8. Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007; 67: 10038-46.
9. Kirn DH, Thorne SH,. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
10. Biondo A, Pedersen JV, Karapanagiotou EM, et al. 1258 POSTER phase I clinical trial of a genetically modified oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. Eur J Cancer 2011; 47: S162.
11. Advani SJ, Mezhir JJ, Roizman B, et al. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 2006; 66: 637-46.
12. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998; 5: 160-5.
13. Twigger K, Vidal L, White CL, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008; 14: 912-23.
14. Liu C, Sarkaria JN, Petell CA, et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155-65.
15. Gridley DS, Andres ML, Li J, et al. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 1998; 13: 1093-8.
16. Mansfield D, Pencavel T, Kyula JN, et al. Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral Oncol 2013; 49: 108-118.
17. Dilley J, Reddy S, Ko D, et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715-22.
18. Adusumilli PS, Stiles BM, Chan MK, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg 2005; 80: 409-16; discussion 16-7.
19. Advani SJ, Buckel L, Chen NG, et al. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res 2012; 18: 2579-90.
20. Wachsberger P, Burd R, Dicker AP,. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-71.
21. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
22. Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009; 14: 1131-8.
23. Hoang T, Huang S, Armstrong E, et al. Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012; 31: 37.
24. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
25. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
26. Frentzen A, Yu YA, Chen N, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009; 106: 12915-20.
27. Chen N, Zhang Q, Yu YA, et al. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med 2009; 15: 144-51.
28. Falkner FG, Moss B,. Transient dominant selection of recombinant vaccinia viruses. J Virol 1990; 64: 3108-11.
29. Chen NG, Yu YA, Zhang Q, et al. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. J Transl Med 2011; 9: 164.
30. Weibel S, Stritzker J, Eck M, et al. Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 2008; 10: 1235-48.
31. Willett CG, Duda DG, Ancukiewicz M, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 845-51.
32. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010; 16: 3067-77.
33. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-15.
34. Freytag SO, Barton KN, Brown SL, et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007; 15: 1600-6.
35. Nishihara E, Nagayama Y, Mawatari F, et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 1997; 138: 4577-83.
36. Kon T, Zhang X, Huang Q, et al. Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA. Transl Cancer Res 2012; 1: 4-14.
37. Sofia Vala I, Martins LR, Imaizumi N, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 2010; 5: e11222.
38. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
39. Brown JM, Wilson WR,. Exploiting tumour hypoxia in cancer treatment. Nature reviews Cancer 2004; 4: 437-47.
40. Jain RK,. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
41. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007; 13: 3395-402.
42. Myers AL, Williams RF, Ng CY, et al. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 2010; 45: 1080-5.